Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.
|Title||Microbial Metabolite Urolithin B Inhibits Recombinant Human Monoamine Oxidase A Enzyme.|
|Publication Type||Journal Article|
|Year of Publication||2020|
|Authors||Singh R, Chandrashekharappa S, Vemula PKumar, Haribabu B, Jala VRao|
|Date Published||2020 Jun 19|
Urolithins are gut microbial metabolites derived from ellagitannins (ET) and ellagic acid (EA), and shown to exhibit anticancer, anti-inflammatory, anti-microbial, anti-glycative and anti-oxidant activities. Similarly, the parent molecules, ET and EA are reported for their neuroprotection and antidepressant activities. Due to the poor bioavailability of ET and EA, the in vivo functional activities cannot be attributed exclusively to these compounds. Elevated monoamine oxidase (MAO) activities are responsible for the inactivation of monoamine neurotransmitters in neurological disorders, such as depression and Parkinson's disease. In this study, we examined the inhibitory effects of urolithins (A, B and C) and EA on MAO activity using recombinant human MAO-A and MAO-B enzymes. Urolithin B was found to be a better MAO-A enzyme inhibitor among the tested urolithins and EA with an IC value of 0.88 µM, and displaying a mixed mode of inhibition. However, all tested compounds exhibited higher IC (>100 µM) for MAO-B enzyme.
|PubMed Central ID||PMC7345905|
|Grant List||R21CA216090; P20GM125504-01 / NH / NIH HHS / United States|